Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

12 novembre 2026 mis à jour par: Cugene Inc.

A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Description détaillée

The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion

Type d'étude

Interventionnel

Inscription (Estimé)

65

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Admin Cugene
  • Numéro de téléphone: 1(781) 893-5800
  • E-mail: admin@cugene.com

Lieux d'étude

    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Recrutement
        • NEXT Virginia

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Signed and dated informed consent.
  2. Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
  3. At least 1 measurable lesion according to RECIST v1.1.
  4. Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  6. Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
  7. Life expectancy of ≥3 months.
  8. Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.

Exclusion Criteria

  1. Rapidly progressing disease or disease requiring urgent alternative medical intervention.
  2. Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
  3. Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
  4. Concurrent participation in another interventional therapeutic clinical trial.
  5. Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
  6. Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
  7. Unresolved clinically significant toxicities from prior anticancer therapy.
  8. Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
  9. Active or clinically significant infection except as specified in the protocol.
  10. Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
  11. Known hypersensitivity or significant allergic reaction to biologics or its components.
  12. Recent vaccination, except as permitted by the protocol.
  13. Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part A Dose Escalation

CUG279 will be administered at multiple ascending dose levels

CUG279 will be administered intravenously according to the protocol

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of dose limiting toxicities (DLTs)
Délai: From the first dose up to 21 days post-dose

The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A.

From the first dose up to 21 days post-dose
Incidence and severity of treatment-emergent adverse events (TEAEs)
Délai: From first dose through 90 days after the last dose

The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of serious adverse events (SAEs)
Délai: From first dose through 90 days after the last dose

The number and percentage of participants with SAEs will be assessed.

From first dose through 90 days after the last dose
Clinically significant changes in safety laboratory parameters from baseline
Délai: From first dose through 90 days after the last dose

Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in electrocardiogram (ECG) findings from baseline
Délai: From first dose through 90 days after the last dose

Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in vital signs from baseline
Délai: From first dose through 90 days after the last dose

Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of TEAEs leading to dose modifications
Délai: From the first dose through the last dose; up to 1 year

The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed.

From the first dose through the last dose; up to 1 year

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Maximum observed plasma concentration (Cmax) of CUG279
Délai: From first dose through 90 days after the last dose

The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Trough plasma concentrations (Ctrough) of CUG279
Délai: From first dose through 90 days after the last dose

The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose

From first dose through 90 days after the last dose
Area under the concentration-time curve (AUC) of CUG279
Délai: From first dose through 90 days after the last dose

The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data.

From first dose through 90 days after the last dose
Terminal half-life (T1/2) of CUG279
Délai: From first dose through 90 days after the last dose

The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Systemic clearance (CL) of CUG279
Délai: From first dose through 90 days after the last dose

The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Volume of distribution (Vz) of CUG279
Délai: From first dose through 90 days after the last dose

The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 antibodies (ADA)
Délai: From first dose through 90 days after the last dose

Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 neutralizing antibodies (NAb)
Délai: From first dose through 90 days after the last dose

Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined

From first dose through 90 days after the last dose
Objective response rate (ORR)
Délai: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Disease control rate (DCR)
Délai: From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Time to response (TTR)
Délai: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1

From the first dose through study completion or until disease progression; up to 1 year
Duration of response (DoR)
Délai: From the first dose through study completion or until disease progression; up to 1 year

Time from first documented CR or PR to disease progression will be determined per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Best overall response (BOR)
Délai: From the first dose through study completion or until disease progression; up to 1 year

Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Progression-free survival (PFS)
Délai: From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 novembre 2026

Achèvement primaire (Estimé)

30 mars 2029

Achèvement de l'étude (Estimé)

30 mars 2029

Dates d'inscription aux études

Première soumission

19 octobre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • CUG279-P101
  • IND 179862 (U.S. FDA IND) (Autre identifiant: FDA)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner